Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chemotherapy-induced Thrombocytopenia Clear all
Completed Phase 2 Interventional

Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

NCT04673266
View directory record Official record
Conditions
Lymphoma Patients, Thrombocytopenia
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 1 Interventional

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

NCT01491594
View directory record Official record
Conditions
Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
Interventions
Eltrombopag
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 82 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

NCT03806556
View directory record Official record
Conditions
Pediatric Cancer, Thrombocytopenia, Hemostatic Disorder, Coagulation Defect; Acquired
Interventions
Tranexamic Acid, Normal saline
Drug
Lead sponsor
Meghan McCormick
Other
Eligibility
2 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

NCT03471078
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Avatrombopag, Placebo Oral Tablet
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Anaheim, California • Bakersfield, California • Riverside, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 4, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035
View directory record Official record
Conditions
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
Interventions
Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

NCT00413283
View directory record Official record
Conditions
Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions
Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
51
States / cities
Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

NCT00102726
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
SB497115, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
27
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

American Trial Using Tranexamic Acid in Thrombocytopenia

NCT02578901
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

NCT00886743
View directory record Official record
Conditions
Severe Thrombocytopenia
Interventions
oprelvekin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Mount Sterling, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT03362177
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
22
States / cities
Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

NCT00002665
View directory record Official record
Conditions
Leukemia, Neutropenia, Thrombocytopenia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
83
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 4, 2026, 8:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

NCT07286032
View directory record Official record
Conditions
Patients With Chemotherapy-Induced Thrombocytopenia
Interventions
Hetrombopag Olamine, Hetrombopag Olamine; Hetrombopag Olamine Placebo
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Long Beach, California • Los Alamitos, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

NCT01147809
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag olamine, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
33
States / cities
Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

NCT01676961
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Thrombocytopenia
Interventions
romiplostim
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

NCT00442871
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

NCT00359463
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 4, 2026, 8:30 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
27
States / cities
Jonesboro, Arkansas • Anaheim, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Recruiting Early Phase 1 Interventional

Single Arm Romiplostim to Prevent CIT

NCT07048249
View directory record Official record
Conditions
Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Interventions
Romiplostim (AMG-531)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Phoenix, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Avatrombopag vs. Placebo for CIT in GI Malignancies

NCT05772546
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions
Avatrombopag, Matching Placebo
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 1 Interventional

A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

NCT01345214
View directory record Official record
Conditions
Chemotherapy-Induced Thrombocytopenia
Interventions
ONO-7746
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Fort Collins, Colorado • Augusta, Georgia • Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

NCT00003619
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
Interventions
filgrastim, vitamin E, busulfan, cytarabine, etoposide, fludarabine phosphate, isotretinoin, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
19 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 4, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

NCT04671901
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746
View directory record Official record
Conditions
Acute Leukaemia
Interventions
Daunorubicin, Cytarabine, Eltrombopag, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 4, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

NCT02052882
View directory record Official record
Conditions
Isolated Chemotherapy-induced Thrombocytopenia
Interventions
romiplostim
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 4, 2026, 8:30 AM EDT